Latest Breaking News On - Michael sofia - Page 1 : comparemela.com

BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders

BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoNew zealand generalNew zealandLonza biologicsAshley nagleFrank mccormickEric huangElisa wymanSchwarz pharmaBowen wallaceAlberto tosoEli wallaceStefan weissMike hannayMark mallon

Arbutus Announces Retirement of Chief Scientific Officer, Michael J Sofia, PhD, Effective December 31, 2024

WARMINSTER, Pa., May 02, 2024 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with.

Michaelj mcelhaughLisam caperelliSecurities exchangeArbutus biopharma corporation nasdaqBiopharma corporationChief scientific officerMichael sofiaInterim presidentChief executive officerLooking statementsSecurities actSecurities exchange actArbutu annual reportArbutu quarterly reports

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript August 3, 2023 Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $0.12. Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Q2 Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. […]

New zealandDave hastingsDavid hastingsKaren simsBrian skorneyRoy buchananMike mackMarket offering programNational cancer institute on unsplashbill collierNational cancer instituteUnsplashbill collierMarket offeringBill collierHealthy subject single ascending doseTech stocksBest healthcare

Arbutus to Present at Jefferies Healthcare Conference

WARMINSTER, Pa., May 31, 2023 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target. | May 31, 2023

Lisam caperelliDavid hastingsWilliam collierArbutus biopharma corporation nasdaqBiopharma corporationJefferies healthcare conferenceNew yorkChief executive officerMichael sofiaChief scientific offerChief financialArbutus biopharma corporation stock exchangePress releaseHat abus ca03879j1003

Arbutus to Present at JMP Securities Life Sciences Conference

WARMINSTER, Pa., May 09, 2023 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target. | May 9, 2023

David hastingsLisam caperelliWilliam collierSecurities life sciences conferenceArbutus biopharma corporation nasdaqBiopharma corporationLife sciences conferenceNew yorkChief executive officerMichael sofiaChief scientific offerChief financialArbutus biopharma corporation stock exchangePress releaseHat abus ca03879j1003